MindBio’s Reports Progress in trials of MB22001 targeting Women’s and Mental Health

The TDR Three Key Takeaways regarding MindBio and Women’s Health:

  1. MindBio initiates Phase 2B trials targeting PMS and PMDD treatment.
  2. Home administration of MB22001 revolutionizes the patient experience
  3. MindBio plans dual listing to attract additional investors and capital if necessary for the MB22001 trials

MindBio Therapeutics (CSE:MBIO, Frankfurt:WF6), specializing in psychiatric treatments, has revealed its latest clinical trials focusing on women’s health, particularly using MB22001, their unique psychedelic medicine. Based in Vancouver, the company targets alternative treatments such as psychedelics to meet the needs in women’s health, especially for conditions like Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD).

MindBio has launched several Phase 2B clinical trials and, in a series of firsts, has gained approval for patients to use MB22001 at home. This form of Lysergic Acid Diethylamide (LSD) is tailored for safe microdosing. Additionally, a recent study by MindBio shows that microdosing MB22001 might improve sleep patterns and overall well-being.

“Microdosing MB22001 could change the way we approach depression treatment, offering a scalable and accessible option,” said Justin Hanka Co-Founder & Chief Executive Officer, highlighting the method’s potential to transform standard depression therapies and address conditions like PMDD. Given that PMS and PMDD disrupt the lives of millions globally, affecting work and relationships, there’s a critical demand for innovative treatments. Traditional therapies such as SSRIs and oral contraceptives are often stopped due to side effects or inefficacy, emphasizing the need for new solutions like MB22001.

MindBio’s innovative trials permit home administration of MB22001, marking an industry first. These include the MDMENS trial, a Phase 1 study evaluating the menstrual cycle’s impact on and tolerance to microdoses of MB22001, and the MDPMD trial, a robust, placebo-controlled study focused on microdosing during the luteal phase.

The company is also set to discuss secondary data from its completed Phase 2A trial of MB22001 in patients with Major Depressive Disorder. They have achieved significant reductions in depression symptoms, meeting primary endpoints using the Montgomery-Asberg Depression Rating Scale (MADRS). This upcoming presentation will provide further insights into the post-treatment effects and continue to support the drug’s development into Phase 3 clinical trials.

“We are eager to share our findings from the women’s health trials and the upcoming Phase 2A data as we move towards the next stages of our growth,” stated Justin Hanka, CEO of MindBio.

Moreover, MindBio is planning a dual listing on major exchanges in the United States or Australia to attract more investment and support their trials, slated for further advancement in 2025. This strategic move aims to enhance investor interest and ensure sufficient funding for ongoing and future trials.

These efforts by MindBio are crucial, not only to their stakeholders but also to the broader field of psychedelic medicine, as they aim to better tailor treatments to women’s specific physiological profiles, thus improving health outcomes and minimizing side effects. 

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More